CD4 and neoplasm: The combination of more immunogenic Ptdss1KD tumor cells and proinflammatory myeloid cells likely resulted in the increase of both effector CD8+ and TH1 CD4+ T cells, predisposing Ptdss1KD tumors to improved response to anti–PD-1 therapy.